//
Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease
Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease
The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short
Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial
A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents